SGLT 2 inhibitor dapagliflozin induced perineal soft tissue infection – A case report
Keywords:Dapagliflozin, Diabetes Mellitus, Fournier’s gangrene, SGLT-2 inhibitors, glucosuria
Herein the author presents a case report of perineal soft tissue infection after starting dapagliflozin in a 55 year old female with type II Diabetes Mellitus. Patient had redness, warmth, tenderness and induration over perineum. After stopping Dapagliflozin and treating her with insulin and IV antibiotics, patient improved clinically. Increased urinary excretion of glucose increases the risk of perineal soft tissue infection in patients with risk factors like obesity, poor perineal hygiene, hypertension, heart failure, very high blood glucose levels and those on immunosuppression. Maintaining perineal hygiene reduces the incidence of perineal soft tissue infection among patients who are on SGLT 2 inhibitor therapy.
Elbeddini A, Tayefehchamani Y, Davey M, et al. Fournier's gangrene with dapagliflozin in a rural hospital: a case report. BMJ Case Rep. 2021;14(2):e237784. Published 2021 Feb 1. doi:10.1136/bcr-2020-237784.
Kasbawala K, Stamatiades GA, Majumdar SK. Fournier's Gangrene and Diabetic Ketoacidosis Associated with Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors: Life-Threatening Complications. Am J Case Rep. 2020;21:e921536. Published 2020 Jun 2. doi:10.12659/AJCR.921536.
Elbeddini A, Gallinger J, Davey M, et al. A Case of Fournier's Gangrene in a Patient Taking Canagliflozin for the Treatment of Type II Diabetes Mellitus. Am J Case Rep. 2020;21:e920115. Published 2020 Feb 24. doi:10.12659/AJCR.920115
How to Cite
Copyright (c) 2023 Dr. Niranjani K, Dr. Madhan L, Dr. Saravanan P, Dr. Dhiran S S
This work is licensed under a Creative Commons Attribution 4.0 International License.
CC BY License